US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US20040226056A1
(en)
*
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
JP4865129B2
(ja)
|
1999-01-13 |
2012-02-01 |
ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク |
タンパク質キナーゼ阻害剤を設計するための新規の方法
|
DE122008000002I1
(de)
*
|
2000-02-15 |
2008-04-17 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
MY128449A
(en)
|
2000-05-24 |
2007-02-28 |
Sugen Inc |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
US6706709B2
(en)
|
2000-06-02 |
2004-03-16 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
EP1296975A1
(en)
|
2000-06-30 |
2003-04-02 |
Sugen, Inc. |
4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
|
ATE399766T1
(de)
|
2000-10-20 |
2008-07-15 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische heterozyklen
|
US6677368B2
(en)
|
2000-12-20 |
2004-01-13 |
Sugen, Inc. |
4-aryl substituted indolinones
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
EP1247809A3
(en)
*
|
2001-03-30 |
2003-12-17 |
Pfizer Products Inc. |
Triazine compounds useful as sorbitol dehydrogenase inhibitors
|
WO2002096361A2
(en)
|
2001-05-30 |
2002-12-05 |
Sugen, Inc. |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
CA2452361A1
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
AR038957A1
(es)
*
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
ES2453164T3
(es)
*
|
2001-08-15 |
2014-04-04 |
Pharmacia & Upjohn Company Llc |
Cristales que incluyen una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, procedimientos para su preparación y sus composiciones
|
MXPA04002242A
(es)
|
2001-09-10 |
2005-03-07 |
Sugen Inc |
Derivados de 3-(4,5,6,7,-tetrahidroindol-2-ilmetiliden)-2-indolinona como inhibidores de cinasa.
|
WO2003031438A1
(en)
*
|
2001-10-10 |
2003-04-17 |
Sugen, Inc. |
3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
|
US7129225B2
(en)
*
|
2001-10-22 |
2006-10-31 |
The Research Foundation Of State University Of New York |
Protection against and treatment of hearing loss
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
TWI259081B
(en)
*
|
2001-10-26 |
2006-08-01 |
Sugen Inc |
Treatment of acute myeloid leukemia with indolinone compounds
|
US20030080191A1
(en)
*
|
2001-10-26 |
2003-05-01 |
Allen Lubow |
Method and apparatus for applying bar code information to products during production
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
EP1466297A4
(en)
*
|
2001-12-17 |
2005-10-19 |
Int Barcode Corp |
AS A SINGLE CODE, DOUBLE-SIDED CODE
|
US20050131733A1
(en)
*
|
2001-12-17 |
2005-06-16 |
Allen Lubow |
Sealable individual bar coded packets
|
DE60205776T2
(de)
|
2001-12-27 |
2006-06-14 |
Theravance Inc |
Indolinon-derivative als protein-kinasehemmer
|
PL372302A1
(en)
*
|
2002-02-15 |
2005-07-11 |
Pharmacia & Upjohn Company |
Process for preparing indolinone derivatives
|
AU2003233576A1
(en)
*
|
2002-05-17 |
2003-12-02 |
Sugen, Inc. |
Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
WO2004016211A2
(en)
*
|
2002-08-08 |
2004-02-26 |
Vanderbilt University |
Pi3k antagonists as radiosensitizers
|
WO2004015082A2
(en)
*
|
2002-08-09 |
2004-02-19 |
Theravance, Inc. |
Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
|
US20040121407A1
(en)
*
|
2002-09-06 |
2004-06-24 |
Elixir Pharmaceuticals, Inc. |
Regulation of the growth hormone/IGF-1 axis
|
HN2003000272A
(es)
*
|
2002-09-10 |
2008-07-29 |
Pharmacia Italia Spa |
Formulaciones que comprenden un compuesto de indolinona
|
AR042042A1
(es)
*
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
AU2003302665B2
(en)
*
|
2002-11-15 |
2009-12-24 |
Symphony Evolution, Inc. |
Kinase modulators
|
US7452913B2
(en)
|
2003-02-24 |
2008-11-18 |
Pharmacia & Upjohn Company |
Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
|
US20040209937A1
(en)
*
|
2003-02-24 |
2004-10-21 |
Sugen, Inc. |
Treatment of excessive osteolysis with indolinone compounds
|
PT2476667E
(pt)
|
2003-02-26 |
2014-09-18 |
Sugen Inc |
Compostos de aminoheteroarilo como inibidores da proteína quinase
|
US7157577B2
(en)
*
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
US20040266843A1
(en)
*
|
2003-03-07 |
2004-12-30 |
Sugen, Inc. |
Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
|
EP1604665B1
(en)
*
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase inhibitor
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
DE10334582A1
(de)
*
|
2003-07-28 |
2005-02-24 |
Basf Ag |
Verfahren zur Herstellung von Maleinsäureanhydrid
|
WO2005023765A1
(en)
*
|
2003-09-11 |
2005-03-17 |
Pharmacia & Upjohn Company Llc |
Method for catalyzing amidation reactions by the presence of co2
|
MXPA06003661A
(es)
*
|
2003-10-02 |
2006-06-05 |
Pharmacia & Upjohn Co Llc |
Sales y polimorfos de un compuesto de indolinona sustituido con pirrol.
|
US20070274981A1
(en)
*
|
2003-10-16 |
2007-11-29 |
Imclone Systems Incorporation |
Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof
|
ES2486240T3
(es)
|
2003-11-07 |
2014-08-18 |
Novartis Ag |
Sales de lactato de compuestos de quinolinona y su uso farmacéutico
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
US20080044881A1
(en)
*
|
2003-11-26 |
2008-02-21 |
Congxin Liang |
Advanced Indolinone Based Protein Kinase Inhibitors
|
EP1699477A2
(en)
*
|
2003-12-11 |
2006-09-13 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
US20050152943A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Medtronic Vascular, Inc. |
Medical devices to treat or inhibit restenosis
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
SE0401790D0
(sv)
*
|
2004-07-07 |
2004-07-07 |
Forskarpatent I Syd Ab |
Tamoxifen response in pre- and postmenopausal breast cancer patients
|
US20060009510A1
(en)
*
|
2004-07-09 |
2006-01-12 |
Pharmacia & Upjohn Company Llc |
Method of synthesizing indolinone compounds
|
PT1786785E
(pt)
*
|
2004-08-26 |
2010-05-21 |
Pfizer |
Compostos amino-heteroarilo enantiomericamente puros como inibidores da proteína quinase
|
AU2005283422C1
(en)
|
2004-09-17 |
2017-02-02 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
CN100432071C
(zh)
*
|
2004-11-05 |
2008-11-12 |
中国科学院上海药物研究所 |
取代1h-吲哚-2-酮类化合物及其制备方法和用途
|
GT200500321A
(es)
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
RU2007135167A
(ru)
*
|
2005-03-23 |
2009-03-27 |
Пфайзер Продактс Инк. (Us) |
Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
|
KR100990027B1
(ko)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
RU2007141654A
(ru)
*
|
2005-05-12 |
2009-05-20 |
Пфайзер Инк. (US) |
Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат
|
RS52243B
(en)
|
2005-05-18 |
2012-10-31 |
Astrazeneca Ab |
HETEROCYCLIC MELT INHIBITORS AND PROCEDURES FOR THEIR USE
|
RU2425041C2
(ru)
|
2005-05-23 |
2011-07-27 |
Новартис Аг |
Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
|
AU2006249790A1
(en)
*
|
2005-05-26 |
2006-11-30 |
The Scripps Research Institute |
Enhanced indolinone based protein kinase inhibitors
|
US20100105031A1
(en)
*
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
PE20080035A1
(es)
|
2005-09-07 |
2008-01-30 |
Amgen Fremont Inc |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
SI1928858T1
(sl)
*
|
2005-09-19 |
2009-10-31 |
Pfizer Prod Inc |
Trde solne oblike s pirolom substituiranega 2-indolinona
|
CA2627598C
(en)
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
RU2008130996A
(ru)
*
|
2005-12-29 |
2010-02-10 |
Дзе Скриппс Ресеч Инститьют (Us) |
Ингибиторы протеинкиназ на основе аминокислотных производных индолинона
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN101007801A
(zh)
*
|
2006-01-27 |
2007-08-01 |
上海恒瑞医药有限公司 |
吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
WO2007124288A1
(en)
|
2006-04-19 |
2007-11-01 |
Novartis Ag |
Indazole compounds and methods for inhibition of cdc7
|
WO2007132307A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
CN101443009A
(zh)
*
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
DE102006024834B4
(de)
*
|
2006-05-24 |
2010-07-01 |
Schebo Biotech Ag |
Neue Indol-Pyrrol-Derivate und deren Verwendungen
|
WO2008001956A1
(fr)
*
|
2006-06-29 |
2008-01-03 |
Eisai R & D Management Co., Ltd. |
Agent thérapeutique contre la fibrose hépatique
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
EP2040738A1
(en)
|
2006-07-13 |
2009-04-01 |
Zymogenetics, Inc. |
Interleukin 21 and tyrosine kinase inhibitor combination therapy
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
TW200817409A
(en)
|
2006-08-04 |
2008-04-16 |
Takeda Pharmaceutical |
Fused heterocyclic derivative and use thereof
|
DK2057156T3
(en)
|
2006-08-23 |
2017-05-08 |
Kudos Pharm Ltd |
2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
CA2662902C
(en)
|
2006-09-15 |
2015-11-24 |
Xcovery, Inc. |
Kinase inhibitor compounds
|
US8053461B2
(en)
|
2006-11-06 |
2011-11-08 |
Theravalues Corporation |
Oxindole derivative
|
MX2009004700A
(es)
|
2006-11-06 |
2009-05-15 |
Supergen Inc |
Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
|
US8084621B2
(en)
|
2006-12-04 |
2011-12-27 |
Jiangsu Simcere Pharmaceutical R&D Co. Ltd. |
3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof
|
JP5319306B2
(ja)
|
2007-01-29 |
2013-10-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
未分化型胃癌治療用組成物
|
DE602008005715D1
(de)
|
2007-02-06 |
2011-05-05 |
Pfizer |
2-amino-5,7-dihydro-6h-pyrroloä3,4-düpyrimidinderivate als hsp-90-inhibitoren zur behandlung von krebs
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
US20090004213A1
(en)
*
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
US20090042906A1
(en)
*
|
2007-04-26 |
2009-02-12 |
Massachusetts Institute Of Technology |
Methods for treating cancers associated with constitutive egfr signaling
|
WO2008138184A1
(fr)
|
2007-05-14 |
2008-11-20 |
Shanghai Hengrui Pharmaceutical Co.Ltd. |
Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
|
WO2008145398A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Pfizer Italia S.R.L. |
4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
|
JP5352476B2
(ja)
|
2007-06-05 |
2013-11-27 |
武田薬品工業株式会社 |
キナーゼ阻害剤としての二環式複素環化合物
|
JP5270553B2
(ja)
|
2007-08-23 |
2013-08-21 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
US20090062368A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
CA2736177A1
(en)
|
2007-09-06 |
2009-03-12 |
Boston Biomedical, Inc. |
Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
|
ES2522365T3
(es)
|
2007-10-11 |
2014-11-14 |
Astrazeneca Ab |
Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
|
KR101513326B1
(ko)
|
2007-11-09 |
2015-04-17 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 항종양성 백금 착물의 병용
|
KR20100069705A
(ko)
*
|
2007-11-21 |
2010-06-24 |
테바 파마슈티컬 인더스트리즈 리미티드 |
수니티닙 헤미-l-말레이트, 이의 다형 및 제조 방법, 라세미 수니티닙 말레이트의 다형, 수니티닙 염기 및 말산을 함유하는 조성물 및 이의 제조 방법
|
US20100256392A1
(en)
*
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
EP2229380A1
(en)
*
|
2007-12-12 |
2010-09-22 |
Medichem, S.A. |
Polymorphic forms of a 3-pyrrole substituted 2-indolinone
|
PL2222675T3
(pl)
|
2007-12-19 |
2014-02-28 |
Genentech Inc |
5-anilinoimidazopirydyny i sposoby zastosowania
|
AU2008340053A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as PI 3 kinase inhibitors
|
US8486963B2
(en)
|
2007-12-21 |
2013-07-16 |
Genentech, Inc. |
Azaindolizines and methods of use
|
JP5399926B2
(ja)
*
|
2008-01-29 |
2014-01-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管阻害物質とタキサンとの併用
|
EP2113248A1
(en)
|
2008-04-29 |
2009-11-04 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
|
EP2090306A1
(en)
|
2008-02-13 |
2009-08-19 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
EA201001125A1
(ru)
*
|
2008-02-13 |
2011-04-29 |
Рациофарм Гмбх |
Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
|
CN101255154B
(zh)
*
|
2008-02-18 |
2011-09-07 |
靳广毅 |
一种取代的2-吲哚啉酮衍生物和制备方法及其应用
|
US20110112164A1
(en)
*
|
2008-02-21 |
2011-05-12 |
Generics (Uk) Limited |
Novel polymorphs and processes for their preparation
|
EP2098521A1
(en)
*
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
WO2009124037A1
(en)
*
|
2008-03-31 |
2009-10-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing sunitinib and salts thereof
|
US8466190B2
(en)
|
2008-04-16 |
2013-06-18 |
Natco Pharma Limited |
Polymorphic forms of Sunitinib base
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
US8829039B2
(en)
|
2008-05-23 |
2014-09-09 |
Shanghai Institute Of Pharmaceutical Industry |
Dihydroindolinone derivatives
|
WO2009154697A2
(en)
*
|
2008-05-28 |
2009-12-23 |
Massachusetts Institute Of Technology |
Disc-1 pathway activators in the control of neurogenesis
|
WO2009150523A1
(en)
*
|
2008-06-13 |
2009-12-17 |
Medichem, S.A. |
Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
|
WO2009157011A1
(en)
*
|
2008-06-23 |
2009-12-30 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
EP2138167A1
(en)
|
2008-06-24 |
2009-12-30 |
ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
WO2009156837A2
(en)
*
|
2008-06-26 |
2009-12-30 |
Medichem, S.A. |
Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
|
DE102008031038A1
(de)
|
2008-06-30 |
2009-12-31 |
Alexander Priv.-Doz. Dr. Dömling |
Sutent zur Anwendung in der Organtransplantation
|
WO2010002933A1
(en)
*
|
2008-06-30 |
2010-01-07 |
Cylene Pharmaceuticals, Inc. |
Oxindole compounds
|
AU2009269149B2
(en)
|
2008-06-30 |
2016-03-17 |
Mesoblast, Inc. |
Treatment of eye diseases and excessive neovascularization using a combined therapy
|
AU2009265360A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Generics [Uk] Limited |
Preparation of 3-pyrrole substituted 2-indolinone derivatives
|
CA2730079A1
(en)
*
|
2008-07-10 |
2010-01-14 |
Generics [Uk] Limited |
Processes for the preparation of crystalline forms of sunitinib malate
|
CA2731605A1
(en)
*
|
2008-07-24 |
2010-01-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
CN102164913A
(zh)
|
2008-07-24 |
2011-08-24 |
麦迪凯姆股份公司 |
一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
|
US8993615B2
(en)
*
|
2008-08-08 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
AU2009288289B2
(en)
*
|
2008-08-25 |
2012-11-08 |
Amplimmune, Inc. |
PD-1 antagonists and methods of use thereof
|
AU2009286521A1
(en)
*
|
2008-08-25 |
2010-03-04 |
Generics [Uk] Limited |
Novel polymorphs of sunitinib and processes for their preparation
|
EP2350129B1
(en)
|
2008-08-25 |
2015-06-10 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
AU2009286520A1
(en)
*
|
2008-08-25 |
2010-03-04 |
Generics [Uk] Limited |
Crystalline form of sunitinib and processes for its preparation
|
MX2011002498A
(es)
*
|
2008-09-05 |
2011-08-04 |
Imp Innovations Ltd |
Derivados de isatina para uso como agentes de formacion de imagenes in vivo.
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
CN102177155A
(zh)
*
|
2008-10-10 |
2011-09-07 |
麦迪凯姆股份公司 |
一种3-吡咯取代的2-吲哚酮苹果酸盐的制备工艺
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
EP2186809A1
(en)
*
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
US20100222371A1
(en)
*
|
2008-11-20 |
2010-09-02 |
Children's Medical Center Corporation |
Prevention of surgical adhesions
|
JP5579619B2
(ja)
|
2008-12-01 |
2014-08-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
UY32351A
(es)
|
2008-12-22 |
2010-07-30 |
Astrazeneca Ab |
Compuestos de pirimidinil indol para uso como inhibidores de atr
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
EP2373643A4
(en)
|
2009-01-02 |
2013-08-07 |
Hetero Research Foundation |
NEW SUNITINIB MALATE POLYMORPHS
|
KR20210151988A
(ko)
|
2009-01-16 |
2021-12-14 |
엑셀리시스, 인코포레이티드 |
암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
|
US8426402B2
(en)
|
2009-02-05 |
2013-04-23 |
Immunogen, Inc. |
Benzodiazepine derivatives
|
JP2012517426A
(ja)
|
2009-02-09 |
2012-08-02 |
アステックス ファーマシューティカルズ インコーポレイテッド |
ピロロピリミジニルaxlキナーゼ阻害剤
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
WO2010098888A1
(en)
*
|
2009-02-27 |
2010-09-02 |
Massachusetts Institute Of Technology |
Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
|
WO2010103094A1
(en)
|
2009-03-13 |
2010-09-16 |
Cellzome Limited |
PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2010108503A1
(en)
|
2009-03-24 |
2010-09-30 |
Life & Brain Gmbh |
Promotion of neuronal integration in neural stem cell grafts
|
CA2758614A1
(en)
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
WO2010120386A1
(en)
|
2009-04-17 |
2010-10-21 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
EP2255792A1
(en)
|
2009-05-20 |
2010-12-01 |
Ratiopharm GmbH |
Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
EP2264027A1
(en)
|
2009-05-27 |
2010-12-22 |
Ratiopharm GmbH |
Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
FR2948940B1
(fr)
*
|
2009-08-04 |
2011-07-22 |
Servier Lab |
Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
EP2475648A1
(en)
|
2009-09-11 |
2012-07-18 |
Cellzome Limited |
Ortho substituted pyrimidine compounds as jak inhibitors
|
AU2010296849A1
(en)
|
2009-09-16 |
2012-05-03 |
Ranbaxy Laboratories Limited |
Salts of sunitinib
|
CN102666545B
(zh)
|
2009-10-20 |
2016-04-06 |
塞尔卓姆有限公司 |
作为jak抑制剂的杂环吡唑并嘧啶类似物
|
US20120271056A1
(en)
|
2009-11-12 |
2012-10-25 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
|
WO2011061613A1
(en)
|
2009-11-19 |
2011-05-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
|
NO2504364T3
(hu)
|
2009-11-24 |
2018-01-06 |
|
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
WO2013022801A1
(en)
|
2011-08-05 |
2013-02-14 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
WO2011095802A1
(en)
|
2010-02-02 |
2011-08-11 |
Generics [Uk] Limited |
Hplc method for analyzing sunitinib
|
WO2011100325A2
(en)
*
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
RU2012139182A
(ru)
|
2010-02-22 |
2014-03-27 |
Ф. Хоффманн-Ля Рош Аг |
ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2011104555A2
(en)
*
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
AU2011222470A1
(en)
|
2010-03-04 |
2012-09-27 |
Ranbaxy Laboratories Limited |
Process for the direct preparation of malic acid salt of sunitinib
|
WO2011107585A1
(en)
|
2010-03-04 |
2011-09-09 |
Cellzome Limited |
Morpholino substituted urea derivatives as mtor inhibitors
|
WO2011110199A1
(en)
|
2010-03-10 |
2011-09-15 |
Synthon B.V. |
A process for amidation of pyrrole carboxylate compounds
|
WO2011114246A1
(en)
|
2010-03-18 |
2011-09-22 |
Ranbaxy Laboratories Limited |
Process for the preparation of malic acid salt of sunitinib
|
WO2011119777A2
(en)
|
2010-03-23 |
2011-09-29 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
WO2011128699A2
(en)
*
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
CA2797772A1
(en)
|
2010-04-30 |
2011-11-03 |
Cellzome Limited |
Pyrazole compounds as jak inhibitors
|
WO2011138565A1
(fr)
|
2010-05-05 |
2011-11-10 |
Biorebus |
Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
|
EP2392324A1
(en)
|
2010-06-01 |
2011-12-07 |
Societe De Coordination De Recherches Therapeutiques |
Rhenium complexes and their pharmaceutical use
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
WO2011162343A1
(ja)
|
2010-06-25 |
2011-12-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
|
WO2012000970A1
(en)
|
2010-07-01 |
2012-01-05 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
RU2571226C2
(ru)
|
2010-07-09 |
2015-12-20 |
Дженентек, Инк. |
Антитела против нейропилина и способы их применения
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
WO2012022681A2
(en)
|
2010-08-20 |
2012-02-23 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
|
US8426418B2
(en)
|
2010-08-27 |
2013-04-23 |
CollabRx Inc. |
Method to treat melanoma in BRAF inhibitor-resistant subjects
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
WO2012058780A1
(en)
|
2010-11-01 |
2012-05-10 |
Scinopharm (Kunshan) Biochemical Technology Co., Ltd. |
Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
|
WO2012059941A1
(en)
*
|
2010-11-04 |
2012-05-10 |
Ind-Swift Laboratories Limited |
Process for preparation of sunitinib malate and salts thereof
|
CN103298794A
(zh)
|
2010-11-09 |
2013-09-11 |
塞尔卓姆有限公司 |
作为tyk2抑制剂的吡啶化合物及其氮杂类似物
|
JP2014503500A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
AR083868A1
(es)
|
2010-12-03 |
2013-03-27 |
Lilly Co Eli |
Compuestos de oxazol[5,4-b]piridin-5-ilo
|
WO2012088522A1
(en)
|
2010-12-23 |
2012-06-28 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
WO2012088529A1
(en)
|
2010-12-23 |
2012-06-28 |
Nektar Therapeutics |
Polymer-sunitinib conjugates
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
MX343337B
(es)
|
2011-02-15 |
2016-11-01 |
Immunogen Inc |
Metodos de preparacion de conjugados.
|
EP2675793B1
(en)
|
2011-02-17 |
2018-08-08 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
EP2675794B1
(en)
|
2011-02-17 |
2019-02-13 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
US8630703B2
(en)
|
2011-03-09 |
2014-01-14 |
Technion Research & Development Foundation Limited |
Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
|
CN102115469A
(zh)
*
|
2011-03-21 |
2011-07-06 |
浙江大学 |
吲哚啉-2-酮类衍生物的制备和用途
|
EP2694511A1
(en)
|
2011-04-04 |
2014-02-12 |
Cellzome Limited |
Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
|
CA2831474A1
(en)
*
|
2011-04-08 |
2012-10-11 |
Beta Pharma Inc. |
New indolinone protein kinase inhibitors
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
CN102898402B
(zh)
*
|
2011-04-26 |
2016-01-20 |
北京大学 |
一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
CA2843195A1
(en)
|
2011-07-28 |
2013-01-31 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as jak inhibitors
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
CN103874699A
(zh)
|
2011-09-20 |
2014-06-18 |
赛尔佐姆有限公司 |
吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
|
CA2849189A1
(en)
|
2011-09-21 |
2013-03-28 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mtor inhibitors
|
JP5995977B2
(ja)
|
2011-10-07 |
2016-09-21 |
セルゾーム リミテッド |
Mtor阻害剤としてのモルホリノ置換二環式ピリミジン尿素またはカルバメート誘導体
|
CN102499917B
(zh)
|
2011-10-25 |
2014-12-17 |
澳门大学 |
吲哚酮类化合物在制备神经保护药物中的应用
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
CN103130774B
(zh)
*
|
2011-11-22 |
2016-06-22 |
齐鲁制药有限公司 |
具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
|
CN103127096B
(zh)
*
|
2011-12-02 |
2015-11-25 |
杨子娇 |
吡咯基取代的吲哚类化合物在治疗青光眼病的应用
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
CN104169272A
(zh)
|
2011-12-23 |
2014-11-26 |
赛尔佐姆有限公司 |
作为激酶抑制剂的嘧啶-2,4-二胺衍生物
|
CN102491932A
(zh)
*
|
2011-12-26 |
2012-06-13 |
天津科技大学 |
一种3-吲哚啉酮类衍生物及其制备方法及其应用
|
EP2828251B1
(en)
|
2012-03-23 |
2018-10-31 |
Laurus Labs Limited |
An improved process for the preparation of sunitinib and its acid addition salts thereof
|
IN2014MN02105A
(hu)
|
2012-04-20 |
2015-09-11 |
Annji Pharm Co Ltd |
|
PL399027A1
(pl)
|
2012-04-27 |
2013-10-28 |
Instytut Farmaceutyczny |
Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
|
CN102653521B
(zh)
*
|
2012-04-27 |
2014-08-06 |
首都师范大学 |
吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
SG11201406550QA
(en)
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
CN104736533B
(zh)
|
2012-08-17 |
2016-12-07 |
癌症治疗合作研究中心有限公司 |
Vegfr3抑制剂
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
ES2907763T3
(es)
|
2012-08-31 |
2022-04-26 |
Sutro Biopharma Inc |
Aminoácidos modificados que comprenden un grupo azido
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Pkm2調節因子およびそれらの使用方法
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
AU2014243869A1
(en)
*
|
2013-03-13 |
2015-09-24 |
Boston Biomedical, Inc. |
3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
|
WO2014152959A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
CN108997225A
(zh)
|
2013-03-14 |
2018-12-14 |
特雷罗药物股份有限公司 |
Jak2和alk2抑制剂及其使用方法
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
CN104119321B
(zh)
*
|
2013-04-28 |
2017-09-08 |
齐鲁制药有限公司 |
二氢吲哚酮衍生物的二马来酸盐及其多晶型物
|
JP6411379B2
(ja)
|
2013-05-14 |
2018-10-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
FR3008411B1
(fr)
*
|
2013-07-12 |
2015-07-03 |
Servier Lab |
Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
|
CN105659085B
(zh)
|
2013-08-28 |
2018-12-07 |
中美冠科生物技术(太仓)有限公司 |
预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US9278955B2
(en)
|
2013-10-18 |
2016-03-08 |
Sun Pharmaceutical Industries Limited |
Ascorbic acid salt of sunitinib
|
CA2838587A1
(en)
|
2013-10-18 |
2015-04-18 |
Hari Babu Matta |
Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
|
AU2014343321B2
(en)
|
2013-11-01 |
2020-02-06 |
Pfizer Inc. |
Vectors for expression of prostate-associated antigens
|
KR20160095035A
(ko)
|
2013-12-06 |
2016-08-10 |
노파르티스 아게 |
알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
|
CN104829596B
(zh)
|
2014-02-10 |
2017-02-01 |
石家庄以岭药业股份有限公司 |
吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
|
CN103923014A
(zh)
*
|
2014-05-05 |
2014-07-16 |
宁夏宝马药业有限公司 |
环肌酸制备方法
|
US9474756B2
(en)
|
2014-08-08 |
2016-10-25 |
Forsight Vision4, Inc. |
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
|
EP3825305A1
(en)
|
2014-08-28 |
2021-05-26 |
Eisai R&D Management Co., Ltd. |
Process for preparing lenvatinib
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
SG11201705767PA
(en)
|
2015-01-13 |
2017-08-30 |
Univ Kyoto |
Agent for preventing and/or treating amyotrophic lateral sclerosis
|
PT3263106T
(pt)
|
2015-02-25 |
2024-01-12 |
Eisai R&D Man Co Ltd |
Método para suprimir o amargor do derivado de quinolina
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
CA2982928A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
CN111349118B
(zh)
|
2015-05-18 |
2023-08-22 |
住友制药肿瘤公司 |
具有增加的生物利用度的阿伏西地前药
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
KR20180018695A
(ko)
|
2015-06-16 |
2018-02-21 |
가부시키가이샤 프리즘 파마 |
항암제
|
CA2993659A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
WO2017053638A1
(en)
|
2015-09-22 |
2017-03-30 |
Graybug Vision, Inc. |
Compounds and compositions for the treatment of ocular disorders
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
KR20180073674A
(ko)
|
2015-11-02 |
2018-07-02 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
|
WO2017083779A1
(en)
|
2015-11-12 |
2017-05-18 |
Graybug Vision, Inc. |
Aggregating microparticles for therapy
|
EP3407917A1
(en)
|
2016-01-27 |
2018-12-05 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
CN109072241A
(zh)
|
2016-02-08 |
2018-12-21 |
维特里萨医疗公司 |
具有改善的玻璃体内半衰期的组合物及其用途
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
CN107459519A
(zh)
|
2016-06-06 |
2017-12-12 |
上海艾力斯医药科技有限公司 |
稠合嘧啶哌啶环衍生物及其制备方法和应用
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
EP3532464A4
(en)
|
2016-10-28 |
2020-07-08 |
Icahn School of Medicine at Mount Sinai |
COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
JP7071392B2
(ja)
|
2016-12-05 |
2022-05-18 |
アプロス セラピューティクス, インコーポレイテッド |
酸性基を含有するピリミジン化合物
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
CN110267659A
(zh)
|
2016-12-08 |
2019-09-20 |
西奈山伊坎医学院 |
用于治疗cdk4/6介导的癌症的组合物和方法
|
EP3362471B1
(en)
|
2016-12-19 |
2021-11-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
CN106916143B
(zh)
*
|
2017-03-14 |
2019-09-27 |
哈尔滨医科大学 |
一种预防和治疗冠心病的药物及其应用
|
AU2018240462C1
(en)
|
2017-03-23 |
2022-12-08 |
Graybug Vision, Inc. |
Drugs and compositions for the treatment of ocular disorders
|
EP3621654A4
(en)
|
2017-05-10 |
2021-02-17 |
Graybug Vision, Inc. |
PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
AU2018333945A1
(en)
|
2017-09-18 |
2020-03-26 |
Sutro Biopharma, Inc. |
Anti- folate receptor alpha antibody conjugates and their uses
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
CA3092677A1
(en)
|
2018-03-06 |
2019-09-12 |
Icahn School Of Medicine At Mount Sinai |
Serine threonine kinase (akt) degradation / disruption compounds and methods of use
|
EP3539536A1
(en)
|
2018-03-15 |
2019-09-18 |
MH10 Spolka z ograniczona odpowiedzialnoscia |
A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
|
WO2020216450A1
(en)
|
2019-04-25 |
2020-10-29 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous sunitinib
|
JP7351859B2
(ja)
|
2018-06-04 |
2023-09-27 |
アプロス セラピューティクス, インコーポレイテッド |
Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
KR20210099066A
(ko)
|
2018-12-04 |
2021-08-11 |
스미토모 다이니폰 파마 온콜로지, 인크. |
암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
|
AU2019407426A1
(en)
|
2018-12-21 |
2021-07-22 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
CN113412262A
(zh)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
包含杂环蛋白激酶抑制剂的制剂
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
MX2021009863A
(es)
|
2019-03-21 |
2021-11-12 |
Onxeo |
Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
|
CN113747895A
(zh)
|
2019-03-22 |
2021-12-03 |
大日本住友制药肿瘤公司 |
包含pkm2调节剂的组合物和用其治疗的方法
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
CA3137916A1
(en)
|
2019-05-06 |
2020-11-12 |
Ichan School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of hpk1
|
US20220298143A1
(en)
|
2019-08-31 |
2022-09-22 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CN111233841A
(zh)
*
|
2020-03-17 |
2020-06-05 |
湖北扬信医药科技有限公司 |
一种舒尼替尼有关物质及其制备方法和用途
|
WO2023278424A1
(en)
*
|
2021-06-28 |
2023-01-05 |
The Regents Of The University Of California |
Methods for treating and ameliorating t cell related diseases
|
CN113717159A
(zh)
*
|
2021-09-16 |
2021-11-30 |
中国药科大学 |
吲哚酮类化合物及其药物组合物、制备方法及用途
|
CA3237696A1
(en)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024017372A1
(zh)
*
|
2022-07-22 |
2024-01-25 |
成都百裕制药股份有限公司 |
一种吲哚酮衍生物及其应用
|